Isla Mackenzie, ESC 2022: Allopurinol for ischaemic heart disease, the ALL-HEART study
The ALL-HEART study is the first large, randomised trial assessing allopurinol in patients with ischaemic heart disease. In this touchCARDIO interview, we speak with Professor Isla Mackenzie (University of Dundee, Dundee, Scotland) to discuss the rationale for the ALL-HEART study, its findings and the future of allopurinol in ischaemic heart disease.
The abstract entitled ‘ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What is the rationale for investigating whether allopurinol improves cardiovascular outcomes in patients with ischaemic heart disease? (0:19)
- What were the aims and design of the ALL-HEART study? (1:24)
- What were the primary and secondary outcome measures and how well were they achieved? (2:01)
- Why do you think these findings failed to reach statistical significance, and what is the future for allopurinol in this indication? (3:06)
Disclosures: Isla Mackenzie is a consultant for Amgen and AstraZeneca and has received grant or research support from British Heart Foundation, EMA, HDR UK, IMI, Menarini, NIHR HTA and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Disease here
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!